AM Rx vs Get Thin MD
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
AM Rx
Best for patients with insurance seeking brand-name GLP-1 access (review regulatory warnings carefully)Starting at $25/mo
Get Thin MD
Best for lowest-priced compounded semaglutide on a 3-month commitment, with brand-name Ozempic/Zepbound also availableStarting at $169/mo
Side-by-Side Comparison
| Feature | AM Rx | Get Thin MD |
|---|---|---|
| Overall Score | 5.9/10 | ✓7.9/10 |
| Starting Price | ✓$25/mo | $169/mo |
| Editorial Rating | 3 ★ /5 | ✓4 ★ /5 |
| Features | 6 features | ✓7 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | 2 warnings | ✓None |
Pros & Cons
AM Rx
Pros
- ✓Insurance coordination for brand-name GLP-1s — as low as $25/mo
- ✓All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
- ✓HSA and FSA accepted
- ✓Video visits available (not just async) with providers averaging 10+ years experience
- ✓Compounded semaglutide from $151/mo quarterly
Cons
- ✗Active FTC/DOJ lawsuit for deceptive billing and subscription practices (ROSCA violations)
- ✗Two FDA warning letters (Sept 2025, Feb 2026) for misbranding compounded GLP-1 products
- ✗Novo Nordisk false advertising lawsuit (Aug 2025)
- ✗Parent entity Zealthy has BBB D- rating with 2,370+ complaints
- ✗Trustpilot 2.0/5 — 85% one-star reviews citing billing disputes and unreachable support
- ✗No visible LegitScript certification or PCAB accreditation
- ✗No named pharmacy partners — compounding source not disclosed
- ✗No FDA compounding disclaimer on the website
- ✗State availability not publicly disclosed
- ✗Founder Kyle Robertson previously ran Cerebral, which settled FTC charges for similar practices
- ✗Same corporate entity (FitRX LLC) as Zealthy and FitRx — shares regulatory history
Get Thin MD
Pros
- ✓3-month compounded semaglutide plan at $169/month is one of the lowest ongoing prices in the compounded GLP-1 category
- ✓Price-lock positioning: 'Same price, every dose. No hidden fees.' — per the product page
- ✓Both compounded and brand-name options available in one platform (compounded semaglutide, compounded tirzepatide, plus brand-name Ozempic and Zepbound where medically appropriate)
- ✓Nationwide availability with async evaluation — no in-person visit required
- ✓Broader wellness platform that also offers sermorelin, NAD+, HRT, and hair-loss treatments, so patients can consolidate multiple protocols with one provider
- ✓Proper FDA compounding disclaimer on the product page: "The FDA does not review or approve any compounded medications for safety or effectiveness."
Cons
- ✗Compounded medications are not FDA-approved as finished products and lack the formal safety/efficacy review of brand-name Ozempic, Wegovy, Zepbound, and Mounjaro
- ✗Pharmacy partners not publicly named on the site — no independent way to verify 503A/503B compounding source or per-batch testing
- ✗State-by-state availability claimed as nationwide but no verbatim state list is published — needs intake signup to confirm whether every state is actually served
- ✗Clinical efficacy headline ("9.6 pounds in 30 days") is based on 645 self-reported patient data points from Jan 2024 – Apr 2025 — self-reported data is lower-quality than a randomized trial
- ✗Broader wellness funnel (sermorelin + NAD+ + HRT alongside GLP-1s) means some patients may be upsold into off-weight-loss protocols — readers looking specifically for GLP-1 care should know the platform has a wider vertical mix
Our Verdict
Get Thin MD edges out AM Rx with a higher overall score of 7.9/10 and is particularly strong for lowest-priced compounded semaglutide on a 3-month commitment, with brand-name Ozempic/Zepbound also available. AM Rx remains a solid alternative, especially if you're looking for patients with insurance seeking brand-name GLP-1 access (review regulatory warnings carefully).
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.